• Eltanexor Inhibits XPO1 to Suppress Wnt/β-catenin in CRC Mod

  2026-05-18

  A recent preclinical study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, reduces colorectal cancer tumorigenesis by modulating Wnt/β-catenin signaling and lowering COX-2 expression. These findings highlight the therapeutic potential of XPO1 inhibition in chemoprevention for high-risk colorectal cancer populations.

• Endothelial STING-JAK1 Axis: Tumor Vessel Normalization and

  2026-05-18

  This study uncovers a novel mechanism in which endothelial STING interacts with JAK1 to regulate tumor vasculature normalization and promote CD8+ T cell-mediated antitumor immunity. The findings clarify the cell-type specificity of STING agonist responses, informing both future therapeutic strategies and experimental design in cancer biology research.

• Indole-3-pyruvic Acid (IPA): Reliable Solutions for Lab Assa

  2026-05-17

  Discover how Indole-3-pyruvic acid (SKU C8759) from APExBIO addresses key challenges in cell viability, proliferation, and immune assays. This article provides scenario-driven, evidence-backed guidance for optimizing IPA use in both plant and mammalian systems, ensuring reproducible and robust results.

• Elbasvir and Grazoprevir: Efficacy and Safety in HCV Genotyp

  2026-05-16

  This article examines the pharmacological innovation, efficacy, and safety of the elbasvir/grazoprevir combination for chronic hepatitis C. Drawing on Wang et al.'s 2021 review, we detail the mechanisms, clinical outcomes, and practical considerations, especially for complex populations such as those with chronic kidney disease or HIV/HCV coinfection.

• Dual Luciferase Reporter Gene System: Mechanisms & Benchmark

  2026-05-15

  The Dual Luciferase Reporter Gene System enables sensitive, normalized quantification of gene expression regulation in mammalian cells. This system uses independent firefly and Renilla luciferase reactions for robust, high-throughput bioluminescence reporter assays. APExBIO’s K1136 kit streamlines workflows, supports direct reagent addition, and offers proven compatibility with multiple media.

• Berberrubine chloride: Multi-Target Mechanisms & Research Pr

  2026-05-15

  Berberrubine chloride is a DMSO-soluble, multi-target isoquinoline alkaloid for scientific research. It demonstrates selective inhibition of IMPDH2 and TrxR, potent anti-colorectal and anti-NSCLC activity, and protocol-driven efficacy in metabolic and cancer models.

• HRP Rabbit Anti-Goat IgG (H+L) Antibody: Precision in Immuno

  2026-05-14

  Unlock robust, low-background detection of goat antibodies in ELISA, western blot, and immunohistochemistry using the HRP Rabbit Anti-Goat IgG (H+L) Antibody from APExBIO. This guide bridges cutting-edge findings from pulmonary toxicology with actionable protocol enhancements and troubleshooting for optimal assay performance.

• Prevotella copri Drives Breast Cancer via IPA Depletion

  2026-05-14

  This study uncovers a direct mechanistic link between gut Prevotella copri colonization and breast cancer progression, mediated by the depletion of host indole-3-pyruvic acid (IPA) and subsequent inactivation of the AMPK pathway via UHRF1. The findings highlight IPA as an intrinsic anti-cancer metabolite and suggest new avenues for microbiome-metabolite-targeted interventions in oncology.

• RITA (NSC 652287): Redefining Precision in Renal Carcinoma R

  2026-05-13

  Discover how RITA (NSC 652287) drives precision in renal carcinoma research through selective p53 activation and advanced in vitro/in vivo models. This article uniquely explores practical assay design, protocol optimization, and nuanced viability analysis.

• L-NMMA Acetate: Benchmarking a NOS Pathway Inhibitor in Rese

  2026-05-13

  L-NMMA acetate is a validated, high-purity inhibitor of all three nitric oxide synthase isoforms. This article details its biological rationale, mechanism, and experimental parameters, supporting its use in nitric oxide pathway modulation within inflammation and regenerative research. Evidence is provided from both peer-reviewed literature and product-specific documentation.

• Anlotinib for IADSRCT: Case Evidence and Research Perspectiv

  2026-05-12

  This article reviews the first documented case of intra-abdominal desmoplastic small round cell tumor (IADSRCT) effectively managed with anlotinib, a multi-target tyrosine kinase inhibitor. The findings highlight anlotinib's promise in rare, treatment-resistant tumors, and provide mechanistic and methodological insights for researchers in cancer biology.

• Talabostat Mesylate (PT-100): Applied Protocols in Tumor Imm

  2026-05-12

  Talabostat mesylate (PT-100) reshapes tumor microenvironment research by targeting DPP4 and FAP, offering a mechanistic bridge from T-cell inflammasome biology to cancer modeling. This article distills actionable workflows, protocol optimizations, and key troubleshooting strategies for leveraging Talabostat in cutting-edge immune modulation and oncology studies.

• RP3-340N1.2 Knockdown Impairs NSCLC via IL-6 mRNA Destabiliz

  2026-05-11

  This study identifies the lncRNA RP3-340N1.2 as a critical driver of non-small cell lung cancer (NSCLC) progression by stabilizing IL-6 mRNA. Knockdown of RP3-340N1.2 not only suppresses tumor cell proliferation and migration but also enhances IL-6 mRNA degradation by promoting ZC3H12A binding, highlighting a promising lncRNA target for future transcriptional regulation research.

• BH3 Mimetics Target Chemotherapy-Induced Senescence in TP53

  2026-05-11

  This study demonstrates that BH3 mimetics selectively eliminate senescent tumor cells after chemotherapy in TP53 wild-type breast cancer. By overcoming the survival advantage of senescent cells, this approach enhances tumor regression and may improve patient outcomes.

• Oligo (dT) 25 Beads: Technical Guide for Eukaryotic mRNA Iso

  2026-05-10

  Oligo (dT) 25 Beads provide a streamlined, magnetic bead-based method for isolating polyadenylated mRNA from eukaryotic samples, enabling efficient downstream applications such as cDNA synthesis and RT-PCR. Use is limited to polyA tail-containing transcripts and is unsuitable for prokaryotic or non-polyadenylated RNA.

455 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page